Polymyxin B and haemofiltration in an adolescent with leukaemia

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1434-

  Scott Baird, J ^a,b  

^a Columbia University ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Clearance; Haemofiltration; Polymyxin B; Sieving coefficient

Indexed keywords

HYPERTENSIVE FACTOR; POLYMYXIN B; PRISMASOL;

ADOLESCENT; ADOLESCENT DISEASE; ANURIA; BLOOD FLOW; CASE REPORT; GRAM NEGATIVE INFECTION; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LETTER; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHATIC LEUKEMIA; RENAL REPLACEMENT THERAPY; SHOCK; STEM CELL TRANSPLANTATION; TREATMENT DURATION; ULTRAFILTRATION;

EID: 84898408215     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt522     Document Type: Letter

References (2)

1. Sandri AM, Landersdorfer CB, Jacob J et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013; 68: 674-7.
2. Thomas TA, Broun EC, Abildskov KM et al. High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 2012; 34: 398-405.